Chair, Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Funda Meric-Bernstam is the surgical oncologist focused on breast surgical oncology. She is Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program at MD Anderson Cancer Center, the Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and The Nellie B. Connally Chair in Breast Cancer at MD Anderson Cancer Center. Her clinical research is focused on Phase I /II trials with novel mechanisms of action, novel combination therapies, and biomarkers to predict and monitor drug response. As Medical Director of the Institute for Personalized Cancer Therapy at MD Anderson, she has not only led large efforts of genomic testing within the institution, but also a) helped build a framework for rapid assessment of actionability of genomic alterations; b) established a Precision Oncology Decision Support Team who can provide point of care input for actionability; c) launched the public website “http://www.personalizedcancertherapy.org” providing access to expert curation of information on therapeutic relevance of specific genes/variants; d) created databases and clinical trial alert systems to facilitate accrual to genotype-selected trials across the institution; and e) monitors trial enrollment after genomic testing to identify approaches to obstacles to trial enrollment.
Disclosure information not submitted.
Wednesday, March 9, 2022
2:51 PM – 3:01 PM CST